Department of Health
and Human Services (HHS)
and Human Services (HHS)
EXPIRED
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Minority Health and Health Disparities (NIMHD)
All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.
Office of Behavioral and Social Sciences Research (OBSSR)
Office of Research on Women's Health (ORWH)
U24 Resource-Related Research Projects Cooperative Agreements
New
RFA-DA-21-022 - HEAL Initiative: HEALthy Brain and Child Development Consortium Administrative Core (U24 - Clinical Trial Not Allowed)
93.279, 93.273, 93.286, 93.113, 93.307, 93.853, 93.313
The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for a Data Coordinating Center for the HEALthy Brain and Child Development Study. This FOA runs in parallel with companion FOAs that solicit applications for linked (RFA-DA-21-020) and unlinked (RFA-DA-21-021) research sites and a single Consortium Administrative Core (RFA-DA-21-022). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, and participate in project data collection and harmonization activities of HBCD research sites. The HBCD Data Coordinating Center (HDCC) will develop (and revise as necessary) the procedures for collection of the core neuroimaging, neuropsychological, and other phenotypic assessment data in a manner that will maximize comparability across the individual research sites of the consortium for the HBCD longitudinal study. The center will perform quality control, data curation, and analysis for the measures collected from the research sites as well as provide data informatics tools for sites and NIH program staff to monitor consortium progress and performance and explore the curated data. The HDCC will facilitate cross-site pooling of data, create a database across assessment modalities, and harmonize with existing large-scale neurodevelopmental research efforts. The successful applicant will propose a secure bioinformatics platform for data storage, harmonization and sharing that enables effective communication of detailed research data, tools for data access and analysis, supporting documentation and necessary training materials. The HDCC should include a director (or co-directors) and one or more associate directors to ensure that the wide scope of activities -- functions of supporting the HBCD Study consortium data and informatics enterprise and acting as a resource center to the scientific community at large -- are seamlessly coordinated.
March 1, 2021
March 31, 2021
No late applications will be accepted for this Funding Opportunity Announcement
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Not Applicable
July 2021
August 2021
September 2021
Not Applicable
It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts).
Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.
Applications that do not comply with these instructions may be delayed or not accepted for review.
HEAL Initiative
This study will be part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information and periodic updates about the HEAL Initiative are available at: https://heal.nih.gov/
Purpose:
The purpose of this FOA is to seeks applications for a Data Coordinating Center for the HEALthy Brain and Child Development Study. The HBCD Data Coordinating Center (HDCC) will develop (and revise as necessary) the procedures for collection of the core neuroimaging, neuropsychological, and other phenotypic assessment data in a manner that will maximize comparability across the individual research sites of the consortium for the HBCD longitudinal study. The center will perform quality control, data curation, and analysis for the measures collected from the research sites as well as provide data informatics tools for sites and NIH program staff to monitor consortium progress and performance and explore the curated data. The HDCC will facilitate cross-site pooling of data, create a database across assessment modalities, and harmonize with existing large-scale neurodevelopmental research efforts. The successful applicant will propose a secure bioinformatics platform for data storage, harmonization and sharing that enables effective communication of detailed research data, tools for data access and analysis, supporting documentation and necessary training materials. The HDCC should include a director (or co-directors) and one or more associate directors to ensure that the wide scope of activities -- functions of supporting the HBCD Study consortium data and informatics enterprise and acting as a resource center to the scientific community at large -- are seamlessly coordinated.
Background:
The brain undergoes rapid development prenatally, through early childhood and into adolescence, supporting cognitive and emotional maturation. This rapid growth also represents a highly vulnerable period where a variety of environmental exposures can have a large and enduring impact. In utero and neonatal exposures are as likely to have significant impact on long-term health outcomes as they are likely to affect early neurodevelopment. For example, substance use during pregnancy, throughout breastfeeding, and while parenting has the potential to profoundly affect development in a variety of ways. Other environmental factors, such as exposure to environmental toxins, structural racism, SARS-CoV-2 exposure and pandemic-related stress, nutritional status, child-rearing practices, neighborhood factors, and access to healthcare, also influence physical growth and brain development. However, the relative paucity of research on normative brain development from birth through adolescence from a large, diverse cohort has limited our ability to fully understand how disruptions and experiences during early periods of growth impact individual developmental trajectories. To understand how these factors, alone and in combination, interact with genetics and other biological influences (e.g., viral exposures) to affect a child’s mental and physical health trajectory, a large prospective study is needed. To be successful, this study must include diverse populations to determine normal variability in development and factors that may disrupt it or build resilience. Additionally, the study must be of sufficient duration and scope to detect potential impact that may manifest as the child approaches school age.
Increases in substance use and ensuing harms over the past decade have heightened the urgency for understanding the complex ways in which exposure during pregnancy affects child outcomes. For example, the current opioid crisis affects the nation broadly across socio-demographic groups, with alarming increases in the use of opioids during pregnancy resulting in a sharp rise in babies born with neonatal withdrawal symptoms (8/1,000 hospital births) in the last 5-10 years. The HEAL Enhanced Outcomes for Infants and Children Exposed to Opioids initiative seeks to support research to address the medical and social needs of infants and children affected by opioid exposure and opioid use disorder. In addition, a growing body of evidence indicates that early exposure to potentially harmful substances, including pre- or perinatally, is linked to greater risk for low birth weight and preterm birth, which portend other health problems. These exposures have also been associated with altered brain structure and function early in life and with behavioral problems in childhood and adolescence, including attention deficit hyperactivity disorder (ADHD), conduct disorder, early drug use, and anxiety. Medications to treat opioid use disorder in pregnant women may mitigate opioid-related harms and improve pregnancy and child outcomes with potential gains projecting into adulthood, but the impact of those medications on neurodevelopment also remains unknown. Moreover, drug exposures during pregnancy are not limited to opioids. Marijuana, tobacco/nicotine, and alcohol are also used alone and in combination with opioids during pregnancy and reports of rising cocaine and methamphetamine use in pregnant women from some geographical areas over the last two decades, with corresponding increases in low birth weight, preterm delivery and maternal morbidity, are also worrisome. Most recently, the COVID-19 pandemic has added another layer of stress to many individuals and families and the virus itself may directly or indirectly affect neurodevelopmental outcomes. Thus, establishing causal links between early exposure to substances or other potential harms and future health and behavioral consequences is complex and will require a large prospective study of children beginning prenatally and followed into childhood. The HEALthy Brain and Child Development (HBCD) Study, is being established to provide a detailed characterization of brain development (using neuroimaging and physiological tools), genetics, social, behavioral, and other biological/environmental contexts to understand neurodevelopmental trajectories. Data collected on this cohort will be made widely available to the scientific community.
To provide an index of normative child development and to address critical questions surrounding the long-term impact of high-risk environments, including substance exposure, HBCD seeks to enroll a large, diverse cohort of pregnant women, who, along with their children, will be followed longitudinally. The cohort will consist of mother and baby dyads recruited beginning in the 2nd trimester of pregnancy and through birth. While a majority of the cohort is expected to be recruited from the general population of pregnant women, a subset will include pregnant women whose babies were exposed pre- or perinatally to prescription and illicit opioids, marijuana, stimulants, alcohol and tobacco/nicotine; as well as women from comparable high risk environments, who did not use substances during pregnancy. Advances in neuroimaging, bioinformatics, and genetic technologies (among others) will enable the collection of multi-modal data that will be made available on an ongoing basis (approximately annually) to the wider research community for timely analysis and as a long-term resource for studying neurodevelopment and other health outcomes. A deep, nuanced understanding of factors that affect a child’s health, brain and behavioral development is expected to emerge from this study, which is an essential first step toward designing policies and interventions that promote well-being and resilience in all children.
For additional information on the planning phase for the HEALthy Brain and Child Development Study, please see the summary reports from expert panel meetings, PI meetings, and neuroimaging and biospecimen workgroups at HBCD Study.
Objectives and Organization of the HEALthy Brain and Child Development (HBCD) Study Consortium
The NIH Helping to End Addiction Long-termSM (HEAL) Initiative and the National Institute on Drug Abuse (NIDA), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), the Office of Behavioral and Social Sciences Research (OBSSR), the Office of Research on Women’s Health (ORWH), the National Institute of Environmental Health Sciences (NIEHS), and the National Institute on Minority Health and Health Disparities plan to establish the HBCD Study that will consist of three, highly integrated components: (1) a single HBCD Data Coordinating Center (HDCC), (2) a single HBCD Consortium Administrative Core (HCAC; RFA-DA-021-022), and (3) a set of HBCD research project sites. Linked and unlinked (see RFA DA-21-020 and RFA DA-21-021) applications for research project sites will be accepted. The HDCC and HCAC cannot be linked. At the time of award, a single consortium will be formed that will together determine the research protocol to be used in the study. Investigators are permitted to apply for only one component (HDCC, HCAC or research site) as the PD/PI, but may serve as co-investigator on more than one component.
This announcement seeks applications to create an HBCD Data Coordinating Center, which will coordinate with a consortium of research sites and an HBCD Consortium Administrative Core in service of a nationwide, multi-site, multi-modal, longitudinal cohort study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes.
The HBCD Data Coordinating Center will serve a role that facilitates the consortium's goal of addressing the following overarching research questions that are central to the HBCD study:
To accomplish these objectives, the NIH HEAL Initiative and several NIH Institutes, Centers, and Offices and Programs plan to support the following:
HBCD Data Coordinating Center (HDCC): This Funding Opportunity Announcement seeks applications for a single data coordinating center that will coordinate, standardize, and integrate all core data collection, processing, storage, and analytic activities of the consortium; facilitate data sharing and serve as a resource to the scientific community to enable broad use of the HBCD data. The HDCC will also provide real-time monitoring of consortium progress and performance.
It is expected that the proposed study will be designed to rigorously address the overarching objectives and research questions outlined above. To support the consortium reaching its stated goals/outcomes, a results-based accountability (RBA) approach will be used for all components. Additional information about the use of RBA for HBCD can be found in section VI. Applicants are reminded that the use of a single Institutional Review Board (sIRB) is required for any multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site (please see the Single IRB Policy for Multi-Site Research).
HBCD Consortium Administrative Core (HCAC): A separate Funding Opportunity Announcement (RFA-DA-21-022) seeks applications for a single HBCD consortium administrative core led by the Program Director(s)/Principal Investigator(s) who is responsible for leadership and management of the HBCD consortium; including, budget, performance, policies, communication, outreach and dissemination plans across the consortium. .
HBCD Research Project Sites: Two separate FOAs (RFA DA-21-020 and RFA DA-21-021) seek applications for a set of linked, multi-site or unlinked single site research projects from a group of investigators (both within and across institutions) whose scientific and technical expertise will allow them to address the objectives and research questions described above. Each research project site will be responsible for participant recruitment and retention, behavioral assessments, biospecimen collection, and neuroimaging. A research project site can be a single institution if all functions (e.g., neuroimaging, biospecimen collection, non-imaging assessments) can be accomplished at that site; or a central hub institution with other institutions as spokes for the hub, such that all the required data collection can be accomplished by the contributing institutions. In either organizational setup, the Program Director(s)/Principal Investigator(s) will have overall responsibility for the progress of the proposed studies.
For additional background information regarding the HBCD study, applicants can review the website (HBCD Study).
HIV/AIDS Counseling and Testing Policy for the National Institute on Drug Abuse: In light of recent significant advances in rapid testing for HIV and in effective treatments for HIV, NIDA has revised its 2001 policy on HIV counseling and testing. NIDA-funded researchers are strongly encouraged to provide and/or refer research subjects to HIV risk reduction education and education about the benefits of HIV treatment, counseling and testing, referral to treatment, and other appropriate interventions to prevent acquisition and transmission of HIV. This policy applies to all NIDA funded research conducted domestically or internationally. For more information see the NIDA Policy on HIV Education, Counseling, Testing, and Treatment for Research Subjects.
National Advisory Council on Drug Abuse Recommended Guidelines for the Administration of Drugs to Human Subjects: The National Advisory Council on Drug Abuse (NACDA) recognizes the importance of research involving the administration of drugs with abuse potential, and dependence or addiction liability, to human subjects. Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects. The guidelines are available on NIDA's website at the NACDA Guidelines for Administration of Drugs to Human Subjects.
Points to Consider Regarding Tobacco Industry Funding of NIDA Applicants: The National Advisory Council on Drug Abuse (NACDA) encourages NIDA and its grantees to consider the points it has set forth with regard to existing or prospective sponsored research agreements with tobacco companies or their related entities and the impact of acceptance of tobacco industry funding on NIDA's credibility and reputation within the scientific community. Please see Points to Consider Regarding Tobacco Industry Funding of NIDA Applicants for details.
Data Harmonization for Substance Abuse and Addiction via the PhenX Toolkit: NIDA strongly encourages investigators involved in human-subjects studies to employ a common set of tools and resources that will promote the collection of comparable data across studies and to do so by incorporating the measures from the Core and Specialty collections, which are available in the Substance Abuse and Addiction Collection of the PhenX Toolkit. Please see NOT-DA-12-008 for further details.
Data Sharing and Archiving: The HBCD Consortium Administrative Core (HCAC), the Data Coordinating Center (HDCC) and HBCD research sites are encouraged to consider additional data sharing, de-identification and archiving policies as set forth by the HEAL Public Access and Data Sharing policy, the NIAAA Data Archive policy, the NIMH Data Archive, and other relevant institutional policies.
See Section VIII. Other Information for award authorities and regulations.
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.
Need help determining whether you are doing a clinical trial?
NIH intends to fund 1 HBCD Data Coordinating Center, corresponding to a total of up to $4,000,000 for fiscal year 2021. Future year amounts are contingent upon annual appropriations.
The maximum project period is five years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Local Governments
Federal Governments
Other
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Applicant organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s)
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
Investigators are permitted to apply for only one component of the overall HBCD Consortium (HDCC, HCAC or research site) as the PD/PI, but may serve as co-investigator on more than one component.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to: [email protected]
Applicants are encouraged to send the letter of intent by email the the email address above but as an alternative the letter may also be sent to:
Office of Extramural Policy and Review
National Institute on Drug Abuse
3WFN 9th Floor, MSC 6021
301 North Stonestreet Ave
Bethesda, MD 20892
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Research Strategy
The application should include plans for Imaging and Neurophysiology, Informatics, Biostatistics, and Data Storage and Data Sharing and workgroups for each. Because the neuroimaging field undergoes continuous technical advances, the HBCD Consortium Administrative Core (HCAC) and the HDCC must plan for integrating technological advances into the longitudinal study and determine how changes in hardware and analytic approaches will be coordinated across multiple research sites. Workgroups within the Consortium will provide the HDCC with recommendations, advice, and decisions in specific areas. Applicants should propose the following required workgroups:
An Imaging and Neurophysiology workgroup within the consortium will make decisions about the design and implementation of specific acquisition protocols for magnetic resonance (MR) imaging (T1-weighted and T2-weighted), diffusion tensor imaging, and resting-state and task-based fMRI data as well as other novel neuroimaging sequences such as relaxometry and magnetic resonance spectroscopy (MRS), and neurophysiological assessments such as electroencephalography (EEG) with and without age-appropriate tasks, that can provide insight into key neurodevelopmental milestones. The HDCC will provide an evaluation of how the protocols will be implemented to facilitate coordinated imaging processing pipelines and harmonization across sites and scanners and will oversee the implementation of any such MRI/EEG acquisition protocol changes that occur throughout the project. The Imaging workgroup will also oversee image processing of the pooled data to provide post-processed data for analysis. The HDCC will work with the HCAC to ensure standardization of neuroimaging and neurophysiological data acquisition protocols and data analysis pipelines. These protocols will require that a common image format (e.g., NIfTI) be used across the different research sites that will facilitate image processing and analysis. This workgroup will ensure that quality control measures are in place at each research site for the acquisition of data (e.g., phantoms). The Imaging and Neurophysiology workgroups would take the lead in processing of the pooled data to provide post-processed data for analysis with collaboration across collection sites to test the broad hypotheses generated by the consortium, and to allow individual investigators to test more detailed specific hypotheses generated as the research projects mature. This workgroup will work with the Consortium Administrative Core to ensure standardization of neuroimaging and neurophysiology data acquisition, protocols, and data analysis pipelines. Because the neuroimaging field undergoes rapid technical advances, the Consortium Administrative Core and the Data Coordinating Center will need to plan for integrating technological advances into the longitudinal study and determine how changes in hardware and analytic approaches will be coordinated across multiple research sites.
An Informatics workgroup will support data collection and reporting infrastructure, including the incorporation of new data collection and analysis domains that emerge from various assessment workgroups (e.g., passive data, mobile technologies) over the course of the longitudinal study. The Informatics workgroup will coordinate the combining of data and the analysis of results across and within research components, and will provide input and consultation on statistics and experimental design. This group will devise methods for integrating data from different levels of analysis from neuroimaging and neurophysiology to the behavioral levels and for linking data from different time points so that data from each study participant can readily be grouped for analysis of neurodevelopmental trajectories. The Informatics workgroup will use a bioinformatics platform for the collection and storage of data generated from the common neuroimaging, neurophysiological, neuropsychological, and clinical assessments, and provide or optimize an interactive user interface for use by all research components. With the establishment of this database, there will also be a need for additional refinement of bioinformatics tools (such as developing interoperable informatics software packages) to facilitate extraction and efficient dissemination of information from the database.
A Biostatistics workgroup will provide input and consultation on all aspects of experimental design and analytical statistics. This workgroup will recommend methods for integrating data from different levels of analysis from the neuroimaging to the behavioral assessments and for linking data from different time points so that data from each study participant can readily be grouped for analysis of neurodevelopmental trajectories. The Biostatistics workgroup will leverage the HDCC data repository and provide an interactive user interface for use by all research components. Additional refinement of bioinformatics tools (such as developing interoperable informatics software packages) to facilitate extraction and efficient dissemination of information from the database is a priority for this longitudinal study.
The HDCC will lead a Data Release workgroup with participation from the HDCC, the HCAC, and other NIH and consortium members as necessary to ensure the efficient and timely upload of data to a public facing portal. Applicants are encouraged to propose use of a specific data repository, or to propose the development of one specific for this purpose. At least an annual data release is expected for the duration of the study.
A Resources workgroup will coordinate a strategic approach to outreach, training and dissemination of HBCD data and informatics resources to the scientific field at large. They will create and execute a plan that will enable scientists from outside institutions (e.g. non-HBCD study research project sites) to utilize the data, specialized tools, techniques, software packages, etc. Facets of this plan should include (but are not limited to), trainings, hackathons, workshops at scientific meetings and conferences to disseminate protocols, standards, data, and other resources for the scientific community to facilitate proper use of the datasets, and publishing white papers (or their equivalent) on best practices and considerations for data collection, pre-processing, analysis, etc.
Functions of the Data Coordinating Center include but are not limited to:
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
The following modifications also apply:
Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed.
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Foreign Institutions
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.
Applications Involving the NIH Intramural Research Program
The requests by NIH intramural scientists will be limited to the incremental costs required for participation. As such, these requests will not include any salary and related fringe benefits for career, career conditional or other Federal employees (civilian or uniformed service) with permanent appointments under existing position ceilings or any costs related to administrative or facilities support (equivalent to Facilities and Administrative or F&A costs). These costs may include salary for staff to be specifically hired under a temporary appointment for the project, consultant costs, equipment, supplies, travel, and other items typically listed under Other Expenses. Applicants should indicate the number of person-months devoted to the project, even if no funds are requested for salary and fringe benefits.
If selected, appropriate funding will be provided by the NIH Intramural Program. NIH intramural scientists will participate in this program as PDs/PIs in accord with the Terms and Conditions provided in this FOA. Intellectual property will be managed in accord with established policy of the NIH in compliance with Executive Order 10096, as amended, 45 CFR Part 7; patent rights for inventions developed in NIH facilities are NIH property unless NIH waives its rights.
Should an extramural application include the collaboration with an intramural scientist, no funds for the support of the intramural scientist may be requested in the application. The intramural scientist may submit a separate request for intramural funding as described above.
Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.
Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Specific to this FOA: Do the investigators have a track record of performing the specialized work required for the project (e.g., processing and integrating data from multiple sites, analyzing and interpreting imaging, neurophysiology and phenotypic data, timely and responsible sharing of data, protocols, specimens to qualified researches, etc.)?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Specific to this FOA: Does the design/research plan include sufficiently innovative elements, as appropriate, that enhance the Study's sensitivity, potential for information sharing to the broader scientific community, and potential to advance data analytic strategies and scientific knowledge?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
Specific to this FOA:
Are adequate plans in place to monitor factors affecting recruitment, enrollment, retention, dropout rates, missed visits, loss to follow-up, and other study parameters within study populations comprising 1) a normative sample that represents the diversity of pregnant women in the U.S. population; 2) a cohort of pregnant women who used opioids and other substances during pregnancy; and 3) a comparison group of pregnant women from similar backgrounds/environments as the cohort of pregnant women who used substances?
Are protocols for data management and quality control of data adequate?
Have the methods for standardization and harmonization of data processing pipelines been satisfactorily addressed?
Is there a detailed plan to make study protocols, a bioinformatics platform and analytical tools available to the larger research community? Does the plan leverage existing infrastructure, tools, systems and resources to implement data curation, pooling, harmonization, dissemination, sharing and analysis through a centralized portal?
Is there a clear plan for communications and training among the involved key personnel, with research sites, the Consortium Administrative Core, NIH institutes and programs, proposed workgroups and other participating entities?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Individuals Across the Lifespan
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
Not Applicable
Renewals
Not Applicable
Revisions
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Not Applicable
Authentication of Key Biological and/or Chemical Resources:
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review (CSR), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications will receive a written critique.
Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit will be discussed and assigned an overall impact score.
Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex. This includes ensuring programs are accessible to persons with limited English proficiency. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html.
HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.
Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.
The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 75, and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this project will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
The PD(s)/PI(s) will be responsible for the scientific and technical direction of the project and agrees to abide by the policies and rules set up by the consortium. This includes accepting the actions and recommendations approved by the Steering Committee. In addition, each PD/PI will agree to accept close coordination, cooperation and participation with the NIH HEAL Initiative and participating NIH ICs in those aspects of management of the project as described below. Each U01 research site project, the U24 data coordinating center, and the U24 consortium administrative core will receive a separate award, and the PI will have control over the project's operating budget. Awardees will be required to attend consortium committee meetings and participate in the cooperative nature of the consortium. Awardees will implement the approved data sharing plan which will be incorporated as an additional term of award, and will be expected to share (make available) these data both within the consortium and with the scientific community. Awardees should comply with their institutional intellectual property policies and practices as approved in the award.
The NIH staff will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
The NIH Project Scientist(s) will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards. The NIH Project Scientist(s) may not be involved in the normal programmatic stewardship of the project including the evaluation of supplemental applications. If such participation is essential, this individual will seek IC waiver. An NIH Program Official will handle the normal stewardship of the award, as described below.
The NIH Project Scientist(s) will have substantial scientific involvement during conduct of this activity, through technical assistance, advice and coordination above and beyond normal program stewardship for grants, as described below. The dominant role and prime responsibility for the activity resides with the awardees for the project as a whole, although specific tasks and activities in carrying out the studies will be shared among the awardees, the NIH Program Official, and the NIH Project Scientist(s).
The NIH Project Scientist(s) will have voting membership (one combined vote) on the Steering Committee and, as determined by that committee, its subcommittees. The NIH Project Scientist(s) will coordinate and facilitate the Consortium project, will attend and participate as a voting member in all meetings of the Steering Committee, and will provide liaison between the Steering Committee, the Consortium, the NIH HEAL Initiative and other involved NIH ICs.
The NIH Project Scientist(s) will assist the Steering Committee in developing and drafting operating policies and policies for dealing with recurring situations that require coordinated action.
The NIH Program Official will review the scientific progress of individual components, and review them for compliance with the operating policies developed by the Steering Committee, and may recommend withholding of support, suspension, or termination of an award for lack of scientific progress or failure to adhere to policies established by the Steering Committee. A results-based accountability approach will be used to support the consortium reaching its stated goals/outcomes. Additional metrics (i.e. % data quality, % missing data points, % participant withdrawals) will be added as a term and condition of the award throughout the duration of this 5-year project. If at any time an outcome is not being met, the program official will ask the PD/PI for a resolution plan and increased progress reporting to ensure compliance. If scientific progress is not met the NIH Program Official may ask the Consortium Coordinator to provide technical assistance and can recommend withholding of support, suspension, or termination of an award for lack of scientific progress or failure to adhere to these award conditions.
The NIH Program Official will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. The NIH Program Official may elect to attend the Steering Committee meetings, but not as a member of the committee.
Areas of Joint Responsibility include:
HBCD Consortium Administrative Core Coordinator’s Rights and Responsibilities: The HCAC coordinator (the PD(s)/PI(s),) is charged with coordinating the scientific and administrative activities of the consortium. The HCAC coordinator has the responsibility for the scientific and technical direction of the research projects, and the administration and overall operation of the consortium. Therefore, the HCAC coordinator is responsible for ensuring that projects awarded are fully integrated within the scientific scope and mission of that consortium. This includes assuring that all investigators have access to the resources within the resource facilities of the consortium. A Steering Committee serves to assist the HCAC coordinator with the governance of the consortium. The HCAC coordinator chairs this committee. In addition, the HCAC coordinator must abide by the operating rules and guidelines developed by the Steering Committee. Furthermore, the HCAC consortium coordinator has agreed to accept participation of NIH staff members in those aspects of management of the project described under "NIH Staff Rights and Responsibilities." Lastly, the HCAC coordinator ensures the timely dissemination of information generated by the consortium component projects to both the consortium project members and the scientific public.
Expert Scientific Board: The consortium includes an Expert Scientific Board whose purpose is to meet with the HCAC coordinator and the Steering Committee to assess progress and provide feedback to the investigators on proposed goals for the next year of support. The panel members are designated by NIH Project Scientist(s) in consultation with the Steering Committee, and consist of research scientists not actively involved with the consortium. The Expert Scientific Board should be formed soon after award and meet with the consortium investigators after the release of the Notice of Award to review and revise the protocol before formal data collection activities begin. Thereafter, the Expert Scientific Board should meet at least once a year immediately prior to the submission of the consortium annual progress report.
Steering Committee: The consortium has a Steering Committee, which is the main governing board of the consortium. The members of the Steering Committee for the consortium are selected by the HCAC coordinator with input from the NIH Project Scientist(s). The Steering Committee is primarily composed of the HCAC coordinator, several principal investigators of the research project components and HDCC component, and the NIH Project Scientist(s). The Steering Committee may, when deemed necessary, invite additional, non-voting scientific advisors to the meetings at which research priorities and opportunities are discussed. The NIH also reserves the right to augment the scientific expertise of the Steering Committee when necessary, and to appoint additional NIH staff as nonvoting members of the Steering Committee and Subcommittees. Each primary member of the Steering Committee has one vote. The chairperson of the Steering Committee is the HCAC coordinator. The Steering Committee may establish subcommittees as it deems appropriate to facilitate the planning and operation of the consortium. The Steering Committee meets at least twice annually to discuss and refine the scientific mission and objectives of the consortium, and to evaluate the scientific progress being made both within the consortium research components and by outside laboratories. The Steering Committee discusses the various experimental approaches that were proposed in the individual components and any relevant new information, and subsequently sets the research priorities for the consortium. In the interest of facilitating research in the neurodevelopment field, the Steering Committee of the consortium evaluates the progress of any new technology being developed and decides when the technology is sufficiently validated for distribution to the research community. The NIH will provide the means to disseminate the technologies and the information related to them.
The Steering Committee will plan one or more meetings a year to which non-consortium participants will also be invited to enable the consortium to explore scientific or technologic advances and innovations that occur during the course of the project. For the second and subsequent years of operation of the consortium, the Steering Committee will plan a symposium or workshop to inform the research community of the progress made. The NIH Program Official and other NIH Project Scientist(s) will provide the Steering Committee with advice on appropriate topics and participants for the workshops and symposia.
Dispute Resolution
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.
A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: [email protected] (preferred method of contact)
Telephone: 301-945-7573
Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: [email protected]
Minki Chatterji
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5435
William Dunty
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-7351
Julia Zehr
National Institute of Mental Health (NIMH)
Telephone: 301-443-1617
Kimberly Gray
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3262
James Griffin
Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD)
Telephone: 301-435-2307
Adam Hartman
National Institute on Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135
Benyam Hailu
National Institute on Minority Health and Health Disparities (NIMH-D)
Telephone: 301-594-8696
Erica Spotts
Office of Behavioral and Social Sciences Research (OBSSR)
Telephone: 301-594-2105
Rebecca DelCarmen-Wiggins
Office of Research on Women's Health (ORWH)
Telephone: 301-451-8689
James A. Griffin, PhD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-2307
Email:[email protected]
Lennin Greenwood
National Institute on Drug Abuse(NIDA)
Telephone: 301.827.6686
Email: [email protected]
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.